Applications of (S)-2-Amino-3-(3,4-Dimethoxy-Phenyl)-Propionic Acid in Industrial Manufacturing

As a specialized manufacturer, we supply (S)-2-Amino-3-(3,4-Dimethoxy-Phenyl)-Propionic Acid for targeted applications in the pharmaceutical, fine chemicals, and research sectors. We focus on supporting established industrial use cases where this chiral amino acid derivative plays a direct role in downstream synthesis and formulation. The following sections outline dedicated application scenarios, including practical dosage guidance, regulatory frameworks, production integration points, and prevalent end products.

1. Active Pharmaceutical Ingredient (API) Synthesis for Antiparkinsonian Agents

Bulk drug manufacturers deploy this compound as a key intermediate for producing APIs used in antiparkinsonian therapeutics. Production environments must meet stringent pharmaceutical standards, as the product’s stereochemistry directly impacts therapeutic function. The intermediate typically enters the synthetic route during the chiral building-block stage and maintains its integrity through subsequent process steps into the final API. Formulators adjust concentration based on target batch size and required conversion rates, with careful process monitoring to avoid racemization.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• US FDA 21 CFR Part 210/211 cGMP for finished pharmaceuticals
• European Pharmacopoeia (Ph. Eur.) monograph requirements for API synthesis
• Chinese Pharmacopoeia (ChP) chemical drug substance standards

Typical usage ratio

• 1.0–1.2 molar equivalents, adjusted for overall yield and process impurity control

Downstream process integration

• Input as a chiral precursor in early or mid-stage step-growth synthesis; undergoes protective group chemistry and coupling reactions before API crystallization

Final product types

• Levodopa analogues (as finished APIs)
• Dopaminergic drug intermediates

2. Peptide Synthesis for CNS Research Compounds

Contract research organizations and biotech companies incorporate this amino acid derivative in solid-phase and solution-phase peptide synthesis to create custom ligands and CNS-active probes. The compound’s stereochemistry is vital for biological assay validity, and production sites must adhere to rigorous analytical and documentation practices. Usage levels depend on peptide length and desired purity, and input happens at the residue assembly stage, typically protected to prevent side reactions.

Industry compliance standards

• ISO 9001:2015 Quality Management for laboratory-scale production
• US Pharmacopeia Chapter <797> for handling chemicals in compounding environments (where applicable)
• Synthetic peptide traceability protocols (GLP guidelines)

Typical usage ratio

• 0.05–0.2 mmol per resin loading, dependent on peptide sequence and chain length

Downstream process integration

• Manual or automated addition after resin swelling and deprotection, with protection group selection based on orthogonality and target deprotection strategy

Final product types

• N-methyl-D-aspartate (NMDA) receptor modulator peptides
• Peptide substrate analogues for CNS function assays

3. Chiral Reference Standard Production for Analytical Laboratories

Analytical standard manufacturers use this compound as a certified reference standard to support chiral purity determination in pharmaceutical quality control, especially in enantioselective HPLC and LC-MS methods. Strict traceability and purity documentation are required under ISO and pharmacopoeial standards. Labs dissolve the compound to prepare calibration mixes, with dosage tailored to instrument sensitivity and linear range requirements.

Industry compliance standards

• ISO 17034:2016 for reference material producers
• European Pharmacopoeia reference standard qualification protocols
• USP General Chapter <11> for reference standards

Typical usage ratio

• 0.1–1.0 mg/mL in mobile phase, based on required calibration curve range and instrument detection limits

Downstream process integration

• Dissolved/aliquoted as a primary chiral reference for calibration solution prep; stored in inert conditions to prevent degradation prior to use

Final product types

• Certified chiral reference standards
• Quality control calibration blends

4. Fine Chemical Intermediate for Heterocyclic Synthesis

Companies specializing in custom synthesis employ this compound as a building block for elaborating substituted aromatic and heterocyclic structures. The high purity is critical for downstream cyclization and condensation reactions, where the methoxy aromatic group guides specific regioselectivity in the synthetic pathway. Usage is dictated by the target compound’s stoichiometry and the process step’s yield characteristics.

Industry compliance standards

• REACH Regulation (EC) No 1907/2006, for safe handling in custom synthesis
• National Institute for Occupational Safety and Health (NIOSH) industrial hygiene controls for laboratory synthesis
• ISO 14001 Environmental Management (for responsible chemical waste practices)

Typical usage ratio

• 0.95–1.1 equivalents, adjusted per target molecule’s reaction scheme and impurity profile

Downstream process integration

• Charged in initial condensation or cyclization steps, often under inert atmosphere with selective catalysts; subsequent functionalization leads toward final heterocycle framework

Final product types

• Substituted benzofurans
• Indole derivatives for fine chemical catalogues

5. Precursor in Neurochemical Probe Manufacture

Innovators in neurochemical research supply utilize this compound to prepare labeled analogues for receptor-binding studies and radiotracer synthesis. Compliance demands absolute traceability, with careful monitoring for isotopic dilution and high-purity requirements at every stage. Input dosage is determined by labeling efficiency and the specific activity desired in the final probe. The raw material enters amid initial conjugation or isotopic labeling steps before final purification.

Industry compliance standards

• ISO/IEC 17025 laboratory process calibration and testing
• Good Laboratory Practice (GLP) standards for research reagents
• Nuclear Regulatory Commission (NRC) isotopic labeling controls (when radioisotopes are used)

Typical usage ratio

• 10–50 μmol per batch, modulated by labeling efficiency and target probe amount

Downstream process integration

• Added at probe backbone assembly or direct labeling step, prior to preparative HPLC purification and final packaging

Final product types

• Isotopically labeled CNS ligand probes
• Radiolabeled receptor binding agents